NovoCure (NVCR)

• Market cap: $2.02B
• 1 day: -0.82%
• 5 days: -4.22%
• 1 month: 1.80%
• 3 months: -28.89%
• 6 months: 6.77%
• Year to date: -39.51%
• 1 year: 48.20%
• 5 years: -72.43%
• 10 years: -0.77%
• Sector: Healthcare
• Industry: Medical Devices

About: NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Employees: 1,488

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

289% more call options, than puts

Call options by funds: $68.8M | Put options by funds: $17.7M

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

88% more capital invested

Capital invested by funds: $1.45B [Q3] → $2.73B (+$1.28B) [Q4]

54% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 35

7% more funds holding

Funds holding: 222 [Q3] → 237 (+15) [Q4]

1.7% less ownership

Funds ownership: 86.3% [Q3] → 84.6% (-1.7%) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 77

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 49% upside
• Avg. target: $30 64% upside
• High target: $34 87% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Piper Sandler Jason Bednar 32% 1-year accuracy 12 / 38 met price target	87% upside $34	Overweight Maintained	23 Apr 2025
Wedbush David Nierengarten 40% 1-year accuracy 46 / 114 met price target	49% upside $27	Neutral Maintained	16 Apr 2025
JP Morgan Jessica Fye 55% 1-year accuracy 21 / 38 met price target	54% upside $28	Neutral Maintained	10 Apr 2025